News-item

Haemonetics Corporation (NYSE; HAE), a global blood management solutions company, today announced that it has entered into a reagent development and supply agreement with Quotient Biodiagnostics Group and its wholly owned subsidiary Alba Bioscience Limited. This arrangement provides Haemonetics with exclusive access to Alba’s comprehensive catalogue of
approved reagents for use in connection with the commercialization of its Arryx laser based blood typing platform. The arrangement includes future milestone payments in connection with the optimization of reagents for use in the Arryx blood typing system.